PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Medical Writing, Alexion Pharmaceuticals, Boston, MA, USA.\', \'Quantitative Sciences, Alexion Pharmaceuticals, Boston, MA, USA.\', \'Clinical Pharmacology, Alexion Pharmaceuticals, Boston, MA, USA.\', \'Department of Clinical Development Sciences, Alexion Pharmaceuticals, Inc., 121 Seaport Boulevard, Boston, MA, 02210, USA.\', \'Department of Clinical Development Sciences, Alexion Pharmaceuticals, Inc., 121 Seaport Boulevard, Boston, MA, 02210, USA. Scott.Rottinghaus@alexion.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1186/s13063-020-04548-z
?:doi
?:hasPublicationType
?:journal
  • Trials
is ?:pmid of
?:pmid
?:pmid
  • 32660611
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.291
?:rankingScore_hIndex
  • 57
is ?:relation_isRelatedTo_publication of
?:title
  • A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32660611>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32660611>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all